CMS Maintaining The Status Quo For ESAs In Chronic Renal Disease

The Centers for Medicare and Medicaid Services has decided not to proceed with a national coverage determination for erythropoiesis-stimulating agents in patients with chronic kidney disease, according to a proposed decision memo released March 16.